tbuckley/cabot-search huggingface dataset:
Cancer center clinic and clinical research team perceptions of identity and interactions.
Authors: David E. Gerber, Torsten Reimer, Sandra Garcia, Mary Gill, Tobi Duncan, Erin Fenske Williams, Simon Craddock Lee
Journal: Journal of Clinical Oncology (2017)

e18215 Background: As evidenced by the NCI-ASCO Teams in Cancer Care Delivery initiative, there is growing interest in applying an emerging science of teams to oncology clinical care. Treatment of patients on cancer clinical trials requires coordination and cooperation among research and clinic teams. However, little empirical research has examined issues of goal alignment, diffusion of responsibility, and perceived rivalries in this setting. Methods: We developed a survey incorporating modified components of the Adapted Team Climate Inventory, the Measure of Team Identification, and the Measure of In-group Bias. Surveys were administered to research staff and clinic staff. Survey responses were analyzed using t tests and ANOVAs. Results: Responses were received from 104 staff (54 clinic, 50 research). Median duration of professional experience was 8.3 years, and median time in current position was 2.0 years. Research staff identified more strongly with their own group ( P&lt; 0.01) but less strongly with the Cancer Center ( P= 0.02) compared to clinic staff. Both clinic and research staff viewed their own group’s goals as clearer than those of the other group ( P&lt; 0.01). Both clinic staff and research staff felt that members of their groups shared information among themselves more than the other group ( P&lt; 0.01). Research staff felt information sharing occurred to a greater extent in both groups than did clinic staff ( P&lt; 0.01). Similar results were noted regarding information sharing with the other group ( Ps&lt; 0.01). Staff indicated that members of their own groups interacted more often with each other than did members of the other group ( P&lt; 0.01), with research staff perceiving higher interaction rates in both teams than clinic staff ( P&lt; 0.01). Research staff perceived daily outcomes to be more important than did clinic staff ( P =0.05), in particular research-related outcomes ( P =0.07). Conclusions: Clinical research staff and clinic staff identify more strongly with their own groups and feel that their own group’s goals are clearer than those of the other group. Further study of interactions, perceptions, and attitudes between research staff and clinic staff is essential to provision of quality care to patients on cancer clinical trials.
TCT-68 Clinical Impact of Post-Stent Optical Coherence Tomography Findings: Two-year Follow-up from a Single Center Registry
Authors: Yuqi Fan, Mitsuaki Matsumura, Allen Jeremias, Alec Goldberg, Masaru Ishida, Akiko Fujino, Evan Shlofmitz, Dragos Alexandru, Elizabeth Haag, Ziad Ali, Jeffrey W. Moses, Gary Mintz, Richard Shlofmitz, Akiko Maehara
Journal: Journal of the American College of Cardiology (2018)
Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment
Authors: Juan J Arroyo-Crespo, Ana Armiñán, David Charbonnier, Leandro Balzano-Nogueira, Francisco Huertas-López, Cristina Martí, Sonia Tarazona, Jerónimo Forteza, Ana Conesa, María J Vicent
Journal: Biomaterials (2018)

The intrinsic characteristics of the tumor microenvironment (TME), including acidic pH and overexpression of hydrolytic enzymes, offer an exciting opportunity for the rational design of TME-drug delivery systems (DDS). We developed and characterized a pH-responsive biodegradable poly-L-glutamic acid (PGA)-based combination conjugate family with the aim of optimizing anticancer effects. We obtained combination conjugates bearing Doxorubicin (Dox) and aminoglutethimide (AGM) with two Dox loadings and two different hydrazone pH-sensitive linkers that promote the specific release of Dox from the polymeric backbone within the TME. Low Dox loading coupled with a short hydrazone linker yielded optimal effects on primary tumor growth, lung metastasis (∼90% reduction), and toxicological profile in a preclinical metastatic triple-negative breast cancer (TNBC) murine model. The use of transcriptomic analysis helped us to identify the molecular mechanisms responsible for such results including a differential immunomodulation and cell death pathways among the conjugates. This data highlights the advantages of targeting the TME, the therapeutic value of polymer-based combination approaches, and the utility of -omics-based analysis to accelerate anticancer DDS.
The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): Results of a pragmatic cluster randomized controlled trial among endometrial cancer patients.
Authors: Lonneke V. van de Poll-Franse, Kim A.H. Nicolaije, Nicole P.M. Ezendam, M. Caroline Vos, Dorry Boll, Johanna MA Pijnenborg, Jan A. Roukema, Roy F.P.M. Kruitwagen
Journal: Journal of Clinical Oncology (2013)

e16517 Background: More patient tailored information for cancer survivors is needed. Evidence on effects of implementing Survivorship Care Plans (SCPs), is limited. Aim of this pragmatic cluster randomized trial is to assess the impact of SCPs in routine clinical practice. Primary endpoint is patient satisfaction with information. Secondary endpoints are QoL and health care use. Methods: We built an SCP-application in the web-based Registrationsystem Oncological GYnecology (ROGY), used in our area since 2006. By clicking the SCP-icon in ROGY, a personalized SCP is automatically generated. Twelve hospitals were randomized to usual care or SCP care. In usual care, gynecologists did not have access to the SCP-icon. In SCP care, SCPs are personally discussed and handed to patients. All newly diagnosed endometrial cancer patients (age ≥ 18) were asked to complete a questionnaire after surgery, 6, 12 and 24 months after diagnosis. The questionnaire included the EORTC INFO25 and asked whether patients actually received an SCP. We expected 150 endometrial cancer patients: 75 per arm. We hypothesized that patients receiving SCP care are more satisfied with the information. Results: 201 patients (74%) returned a questionnaire after surgery: 109 SCP arm, 92 usual care arm. Of the patients in the SCP arm, 69% reported receiving an SCP. Analyses according to randomization arm showed that patients in both arms reported similar scores on all scales of the INFO25, including satisfaction with care (87% vs. 82%, SCP vs usual care, p=0.20). Analyses according to actual care received showed that patients who received SCP care reported significantly higher scores (4-18 points) on all scales of the INFO25, including satisfaction with care (91% vs. 78%, SCP vs usual care, p=0.046) compared to those who did not receive SCP care. Conclusions: Even in a situation where SCPs are automatically generated, still one third does not receive an SCP. But, those who receive SCP care report better information provision and satisfaction. Follow-up measures will show whether this ultimately results in better QoL and decreased health care use. Clinical trial information: NCT01185626.
Which is better? Carboplatin versus cisplatin for locally advanced cervical cancer chemo-radiation: Peruvian experience.
Authors: Natalia Valdiviezo, Nathaly Poma Nieto, Victor Paitan Amaro, Connie Rabanal, Jule Franve Vasquez Chavez, Luis Mas
Journal: Journal of Clinical Oncology (2016)

e17018 Background: Cervical cancer is the most common malignancy in women in Peru. The standard primary treatment of locally advanced disease is chemo-radiation. The election drug is platinum salts, clinical guidelines recommend cisplatin. In some institutions Carboplatin is commonly used because of its safe toxicity profile and its synergy with radiation reported in other malignancies, besides it is not clear use of it. In this study we want to report our experience using Carboplatin and cisplatin concurrent to radiotherapy in terms of response rates and toxicity. Methods: Retrospective observational analysis. Our main objective was to compare the response rate and toxicity profile between Carboplatin and cisplatin chemo-radiation in women older than 18 years old, with diagnosis by biopsy of locally advanced cervical cancer ( stages Ib2 – IVA) of the “Instituto nacional de enfermedades neoplasicas”, Lima ,Peru in 2014 and 2015. The stage was determined clinical evaluation and abdominal- pelvic CT. We determined two arms; cisplatin 40 mg/m2 per week for 5 weeks and Carboplatin 2AUC per week for 5 weeks. Both groups were concurrent with radiotherapy. Results: We evaluated 250 patients, 121 were in the carboplatin arm and 129 patients in the cisplatin arm. The groups have similar characteristics. The median age was 50.9 years. In cisplatin arm, histologic type was squamous cell carcinoma 93%, IIB 75% and IIIB 21%, with complete response rate of 85%. In carboplatin arm the histologic type was squamous cell carcinoma 91%, there were stage IIB 62% and IIIB 31%, with complete response rate 71%. The toxicity profile in cisplatin arm was non haematological grade 2- 3: diarrhea 25%, emesis 23% and haematological grade 1- 2 anemia 31%, neutropenia 27%, thrombocytopenia 6%. The toxicity in carboplatin arm was non haematological grade 2- 3: renal 4%, diarrhea 15%, emesis 18% and haematological grade 1- 2 anemia 37%, neutropenia 27%, trombocitopenia 6%. The overall survival and disease free survival are ongoing. Conclusions: Our study found that carboplatin is an active agent with an acceptable toxicity profile. This intervention remains to be clarified with following-up.
TCT-794 Effect of Atrial Fibrillation in Asian Patients With Angina Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Korean Nationwide Study
Authors: Yong Giun Kim, Gyung-Min Park, Soe Hee Ann, Jae-Hyung Roh
Journal: Journal of the American College of Cardiology (2018)
A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).
Authors: Brian Koffman, Betsy Dennison, Kaitlin Kennard, John C. Byrd, John M. Pagel, Matthew Steven Davids, Chadi Nabhan, Neil E. Kay, Tanya Siddiqi, Danielle M. Brander, Deborah Marie Stephens, Brian Thomas Hill, Javier Pinilla-Ibarz, Bruce D. Cheson, Steven T. Rosen, Farrukh Tauseef Awan, Michael Y. Choi, Anthony R. Mato
Journal: Journal of Clinical Oncology (2018)

7532 Background: The CLL literature focuses largely on the objective aspects of diagnosis (dx), active observation (AO), prognosis and management. While health care providers (HCPs) try to effectively educate and reassure pts, the literature on pts’ subjective experience through the continuum of care is limited. Methods: We utilized an online or paper 64 question survey directed to CLL pts to capture more information on their experience with CLL. The survey was IRB-approved and took place between October-December 2017. All analyses here are descriptive in nature. Results: 1147 pts from 48 states completed the survey. Median age was 65 (range 28-86), 46% male, 96% Caucasian. 33% of pts do not recall education by their HCP at dx. Following education, 66% of pts report a good understanding of sources of information on CLL, 64% of disease characteristics and 62% of therapy indications. At disease progression, only 23% of pts report education from their HCPs. Effects of treatment and clinical trial opportunities are well understood by 43% and 35% respectively. At dx, 48% were told they had the “good” cancer. When AO was recommended, pts report anxiety (56%), relief (52%) and confusion (31%). 34% and 16% of pts report that discussing prognostics increased their anxiety and confusion respectively. During AO pts report fatigue (51%), enlarged nodes (47%), anxiety (39%), depression (21%), and night sweats (21%). Also during AO, 653 pts (66%) utilize herbals and other non-traditional interventions for CLL management (Table). When pts declined participation in a clinical trial, the reasons cited were preference for a “proven” treatment (38%), distance from the trial site (29%), fear (20%), and frequent imaging (20%). Conclusions: To our knowledge, this is the largest survey of CLL pts. Much can be learned by detailed surveying of CLL pts throughout their disease. These include previously unrecognized suboptimal interactions between the CLL pt and the HCP. Understanding how pts experience their disease is critical to improve communication between pts and their HCPs, which will ultimately advance CLL outcomes. During AO % used Green tea or derivatives 60 Vitamin D 56 Prayer 36 Exercise 30 Curcumin 27 Other herbs / supplements 26
Does ethnicity influence cardiac survival among cancer patients?
Authors: Muneer J Al-Husseini, Mohamed M Gad, Anas M Saad, Abdelrahman Aboulshouk, Haris Riaz, Haitham Ahmed
Journal: Journal of Clinical Oncology (2018)

e22114 Background: With increasing survival of cancer patients owing to diagnostic and treatment improvements, cardiac death assumes an ever-increasing role across US cancer survivors. Herein, we investigate whether cardiac related death is influenced by the ethnicity of cancer patients. Methods: The Surveillance Epidemiology and End Results ‘SEER’ program of the National Cancer Institute was queried to survey all cancer patients in SEER 18 Registries diagnosed between 1973 and 2014 and who died of cardiac . We used Kaplan-Meier test to calculate cardiac specific survival among Ethnicities (White, Black, Asian/Pacific Islander, American Indian/Alaska Natives and Hispanics). Multivariable covariate-adjusted Cox model was used to adjust for age at diagnosis, sex, site, and cancer stage. Results: A total of 9,675,661 patients with a cancer diagnosis were queried, and of those, ,998 died of cardiac causes. Median53.00 months (95% CI, 52.69-53.30). Whites constituted most of the sample (336,799), others were Blacks, Asians/Pacific islanders, American Indians/Alaska natives, or Hispanics (40,498, 15,968, 1,101, and 18,632 respectively). Kaplan Meier curves (Figure) showed a statistically significantly higher survival of Whites when compared to Blacks, American Indian/Alaska natives, or Hispanics ( p < .). However,, there was no significant difference between whites and Asians or Pacific islanders (p = .074). The hazard ratio of cardiac death in Blacks, Asians/Pacific islanders, American Indians/Alaska natives, and Hispanics vs Whites were 1.315, 0.995, 1.202, and 1.149 respectively. These findings remained robust after multivariate adjustments for age, gender, site and cancer stage. Conclusions: Minority cancer survivors are at a significantly higher risk of cardiac mortality compared to white survivors. These results cannot be attributed to differences in cancer therapy since all patients died of non-cancer related causes. Further research is needed to better understand the discrepancies in these outcomes.
<i>HSD3B1</i> genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
Authors: Jason W.D. Hearn, Wanling Xie, Mari Nakabayashi, Nima Almassi, Chad A. Reichard, Mark Pomerantz, Philip W. Kantoff, Nima Sharifi
Journal: Journal of Clinical Oncology (2017)

5050 Background: The enzyme encoded by the HSD3B1(1245C) variant allele has been shown to promote castration-resistant prostate cancer by increasing intratumoral dihydrotestosterone synthesis. In the setting of biochemical recurrence (BCR) following prostatectomy, inheritance of the variant allele has been associated with inferior clinical outcomes for men treated with androgen deprivation therapy (ADT). Whether the same is true in the context of BCR after radiotherapy (RT) is unknown. Methods: We determined HSD3B1 genotype retrospectively in men treated with ADT for post-RT BCR using an established biorepository at a large academic center. We analyzed time-to-progression (TTP), time-to-metastasis (TTM), and overall survival (OS) according to HSD3B1genotype using an additive genetic model with the log-rank trend test. Multivariable analyses (MVA) were performed to adjust for known prognostic factors with Cox regression. Results: We identified 218 men treated with ADT for BCR after RT, of whom 213 (98%) were successfully genotyped (46%, 45% and 9% carrying 0, 1, and 2 variant alleles, respectively). Median follow-up was 7.9 years (yrs). Demographic and treatment factors were similar across genotypes. Median TTP was 2.3 (95% CI: 1.6, 3.1) yrs in men who inherited 0 variant alleles, 2.3 (1.5, 3.3) yrs with 1 variant allele, and 1.4 (0.7, 3.3) yrs with 2 variant alleles (P = 0.683). Median TTM diminished with the number of variant alleles inherited (7.4 [6.7, 9.7], 5.8 [4.9, 6.5] and 4.4 [3.0, 5.7] yrs, respectively (P = 0.030). No difference in OS was detected (P = 0.305). On MVA with 0 variant alleles as the reference, the adjusted hazard ratio (HR) for metastasis was (1.19 [0.74, 1.92]; P = 0.480) for 1 allele and (2.01 [1.02, 3.97]; P = 0.045) for 2 alleles. MVA did not demonstrate significant differences in TTP or OS. Conclusions: The HSD3B1(1245C) allele that enhances dihydrotestosterone synthesis is associated with time-to-metastasis in men treated with ADT for BCR after RT for prostate cancer. Notably, 49% of men had received prior ADT as part of local therapy and 56% received an anti-androgen during ADT for BCR, which may blunt the effect of the variant allele.
Impact of cancer on employment and finances in young adult (YA) survivors.
Authors: Tyler Garrett Ketterl, Jacqueline N. Casillas, Patricia A. Ganz, Linda A. Jacobs, Mary S. McCabe, Steven C Palmer, Ann H. Partridge, Emily Jo Rajotte, Betsy C Risendal, Donald Rosenstein, Karen L Syrjala, K. Scott Baker
Journal: Journal of Clinical Oncology (2018)

10013 Background: YA survivors face challenges unique from those survivors of childhood cancer or older adults. The potential impact of cancer or its treatment upon employment and financial burden in YAs are not fully known. Methods: Eligibility included diagnosis of malignancy between ages 18-39, 1-5 years from diagnosis and ≥1 year from therapy completion. Participants were randomly selected from tumor registries of 7 participating sites and asked to complete an online patient reported outcomes survey. Diagnostic/treatment data were abstracted from medical records. Results: Subjects included 872 survivors, 72.3% female, grouped into 4 diagnostic categories: breast (n = 209), thyroid (n = 104), lymphoma (n = 91), and other (n = 332) including brain tumors. Most survivors (736, 84.4%) reported working for pay at some time between diagnosis and survey completion and 517 (70.2%) reported a physical component to their job and that their cancer/treatment interfered with their ability to perform the physical (58.6%) or mental (54.2%) job tasks required. Males were more likely to be working for pay any time after diagnosis (OR1.6, 95% CI 1.0-2.5, p = 0.05). Survivors treated with surgery alone were less likely to have impairments limiting their ability to perform physical (OR 0.5 95% CI 0.3-0.7, p < 0.005) or mental tasks (OR 0.4, 95% CI of 0.3-0.5, p < 0.005) at work compared to those treated with chemotherapy +/- radiation. 56.6% reported taking extended paid or unpaid time off from work, or made a change in their hours, duties or employment status and 95.6% of those reported this was related to their cancer/treatment. Unpaid time off from work was taken by 286 survivors (38.9%) with 107 (37.4%) of those taking > 6 months unpaid time off. Survivors in the “other diagnosis” category were significantly more likely to have taken unpaid time off work (OR of 1.5, 95% CI 1.0-2.2, p = 0.015). Nearly 1/3 of all survivors reported that they/their family borrowed money or went into debt because of cancer/treatment; 47.2% with debt borrowed > $10,000 and 13 (4.9%) reported bankruptcy. Conclusions: In YA survivors, cancer/treatment has a significant impact on the physical and mental activities of their jobs and many report ongoing work limitations > 1 year from therapy completion.
Age-Associated Trends in Diagnosis and Prevalence of Infection with HIV Among Men Who Have Sex with Men — United States, 2008–2016
Authors: Andrew Mitsch, Sonia Singh, Jianmin Li, Alexandra Balaji, Laurie Linley, Richard Selik
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In 2016, two thirds of diagnosed human immunodeficiency virus (HIV) infections in the United States were attributed to male-to-male sexual contact (1). The risk for sexual acquisition and transmission of HIV changes through the lifespan (2); to better guide prevention efforts for gay, bisexual, and other men who have sex with men (MSM*), CDC analyzed National HIV Surveillance System† (NHSS) data for MSM aged ≥13 years by age group (13-29, 30-49, and ≥50 years) in 50 states and the District of Columbia (DC). During 2008-2016, the annual number of diagnoses of HIV infection increased 3% per year among MSM aged 13-29 years, decreased 4% per year among those aged 30-49 years and was stable for MSM aged ≥50 years. The number of HIV diagnoses among MSM aged 13-29 years was four times that of MSM aged ≥50 years. During 2008-2015, the number of MSM aged ≥50 years living with diagnosed HIV infection (prevalence of HIV infection) increased an average of 11% per year and at year-end 2015 was three times that of MSM aged 13-29 years. Racial/ethnic disparities in HIV infection persisted, particularly among younger black/African American MSM who accounted for 49% of all diagnoses among MSM aged 13-29 years during 2008-2016. To avert the most infections and improve health outcomes (3), sexually active MSM at risk for HIV infection should be tested at least once a year, and, if positive, linked to and retained in HIV medical care to achieve viral suppression (4). Those testing negative should be provided HIV prevention services, including preexposure prophylaxis (PrEP) (5).